Escobar, M., Luck, J., Averianov, Y., Ducore, J., Fernández, M. F. L., Giermasz, A., Hart, D. P., Journeycake, J., Kessler, C., Leissinger, C., Mahlangu, J., Martinez, L. V., Miesbach, W., Mitha, I. H., Quon, D., Reding, M. T., Schved, J., Stasyshyn, O., Vilchevska, K. V., Wang, M., Windyga, J., Alexander, W. A., Al‐Sabbagh, A., Bonzo, D., Mitchell, I. S., Wilkinson, T. A., & Hermans, C. (2021). pERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia, 27(6), 911–920. http://access.bl.uk/ark:/81055/vdc_100146335568.0x000039